Publications by authors named "A Totaro"
: A comprehensive comparison of intraoperative, oncological, and functional outcomes of RARP performed with different robotic surgical platforms is critically needed. Our aim is to compare the oncological and functional outcomes of RARP performed using the novel Hugo™ RAS system with those from the daVinci system, the reference standard, at a high-volume robotic center, with an extended follow-up period (one year). : We analyzed the data of 400 patients undergoing RARP ± pelvic lymph node dissection between 2021 and 2023, using propensity score (PS) matching to correct for treatment selection bias.
View Article and Find Full Text PDFIntroduction: Benign prostatic hyperplasia (BPH) is a prevalent urological condition leading to lower urinary tract symptoms. Minimal invasive surgical treatment (MISTs) such as Rezūm System are emerging aiming to relieve symptoms. We present results from a single centre prospective study.
View Article and Find Full Text PDFBackground And Objective: The introduction of the Hugo RAS system represents a recent innovation in robotic surgery. The potential benefits and limitations of this system and its integration into clinical practice in urology have yet to be fully delineated. Our objective was to assess surgical, early oncological, and functional outcomes in studies comparing robot-assisted radical prostatectomy (RARP) performed with the new Hugo RAS system and the well-established da Vinci surgical system.
View Article and Find Full Text PDFThe mental and emotional status after radical cystectomy and different urinary diversion orthotopic bladder substitution versus external urinary diversion after radical cystectomy: A propensity score-matched study.
Int J Urol
December 2024
Article Synopsis
- - The study investigates the effects of two types of urinary diversion—Bricker's ureteroileocutaneostomy and orthotopic bladder replacement—on the quality of life in patients undergoing radical cystectomy for bladder cancer over a time span from January 2020 to February 2024.
- - Participants completed four different quality of life questionnaires before surgery and at 3 and 12 months post-surgery, revealing statistically significant improvements in various functional aspects and symptoms, particularly in the neobladder group.
- - While the neobladder showed better results in certain areas, the study concludes that there isn't a clear winner between the two urinary diversion methods, emphasizing the importance of collaborative decision-making among patients, caregivers, and healthcare
The 2024 ASCO Genitourinary Cancer Symposium, this year celebrating the 20th anniversary, delved into key advancements in urothelial carcinoma (UC) and prostate cancer (PC). For UC, insights emerged from adjuvant pembrolizumab for muscle-invasive urothelial carcinoma, and from the efficacy of the EV-302 study of enfortumab vedotin +pembrolizumab in the metastatic setting. In PC, adjuvant therapy with high-dose radiotherapy schedules plus long-t erm ADT was explored.
View Article and Find Full Text PDF